MLTX May 2024 35.000 call
| Previous close | 13.6000 |
| Open | 5.0000 |
| Bid | 3.6000 |
| Ask | 6.1000 |
| Strike | 35.00 |
| Expiry date | 2024-05-17 |
| Day's range | 5.0000 - 5.0000 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
GlobeNewswireMoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa VELA is the first Phase 3 program in hidradenitis suppurativa to use the higher clinical response level of HiSCR75 as the primary endpoint The topline primary endpoint readout at week 16, together with data on other endpoints, is expected as of mid-2025 Program will evaluate sonelokimab for a total of 52 weeks, across VELA-1 and VELA-2, at sites in the
- GuruFocus.com
MoonLake Immunotherapeutics Reports Q1 2024 Financial Outcomes
Details on Clinical Advances and Financial Health Amidst Ongoing Research and Development Efforts
- GlobeNewswire
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update Announced positive feedback from both FDA and EMA on the regulatory path for the Phase 3 program of the Nanobody® sonelokimab in hidradenitis suppurativa (HS) and outlined the development plan with topline results anticipated in mid-2025Reported significant improvements observed across all key outcomes with sonelokimab over 24 weeks in the ARGO Phase 2 trial in active psoriatic arthritis (PsA)
